美国 - 英文 - NLM (National Library of Medicine)

teva parenteral medicines, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 50 mg in 2 ml

美国 - 英文 - NLM (National Library of Medicine)

teva parenteral medicines, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 25 mg in 1 ml

美国 - 英文 - NLM (National Library of Medicine)

sagent pharmaceuticals - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 50 mg in 2 ml

美国 - 英文 - NLM (National Library of Medicine)

areva pharmaceuticals - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate injection is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate injection in previously untreated or non-refractory patients with cll have not been established. none [see warnings and precautions (5.6)]. based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of fludarabine phosphate injection in pregnant women. in rats, repeated intravenous doses of fludarabine phosphate at 2.4 times and 7.2 times the recommended human intravenous dose (25 mg/m 2 ) administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (cleft palate, exencephaly, and fetal vertebrae deformities) and decreased fetal

美国 - 英文 - NLM (National Library of Medicine)

lannett company, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate injection is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate injection in previously untreated or non-refractory patients with cll have not been established. none [see warnings and precautions (5.6)]. based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of fludarabine phosphate injection in pregnant women. in rats, repeated intravenous doses of fludarabine phosphate at 2.4 times and 7.2 times the recommended human intravenous dose (25 mg/m 2 ) administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (cleft palate, exencephaly, and fetal vertebrae deformities) and decreased fetal body weights. m

加拿大 - 英文 - Health Canada

omega laboratories limited - fludarabine phosphate - liquid - 25mg - fludarabine phosphate 25mg - antineoplastic agents

加拿大 - 英文 - Health Canada

mylan pharmaceuticals ulc - fludarabine phosphate - solution - 25mg - fludarabine phosphate 25mg - antineoplastic agents

加拿大 - 英文 - Health Canada

teva canada limited - fludarabine phosphate - solution - 25mg - fludarabine phosphate 25mg - antineoplastic agents

加拿大 - 英文 - Health Canada

fresenius kabi canada ltd - fludarabine phosphate - solution - 25mg - fludarabine phosphate 25mg - antineoplastic agents

加拿大 - 英文 - Health Canada

fresenius kabi canada ltd - fludarabine phosphate - powder for solution - 50mg - fludarabine phosphate 50mg - antineoplastic agents